Expression of and and Serum Level of Adiponectin in Gastric Cancer.

Background: Cancer is one of the major causes of death worldwide and the third leading cause of death in Iran. One of the proteins that are considered having anticancer effects is the adiponectin hormone. Adiponectin leads to programmed cell death, prevents cell growth and proliferation, and increases the expression levels of .

A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial.

Background: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of B cells in blood, lymphoid tissues and bone marrow. Addition of rituximab to CLL chemotherapy regimens has been associated with improved survival. The aim of this study was to establish efficacy and safety of Zytux™ in comparison to MabThera in treatment of CLL.

Craniospinal dissemination of filum myxopapillary ependymoma following spinal trauma: case report and literature review.

Background: Myxopapillary ependymoma is a rare benign variant of ependymoma, occurring most commonly in the cauda equina/filum terminale of the spinal cord. It is rare in pediatric patients. Dissemination of the myxopapillary ependymoma along the neuraxis is uncommon both in adults and pediatric patients.

Primary spinal epidural rhabdomyosarcoma: a case report and review of the literature.

Background: Primary intraspinal sarcomas are very rare in children. Rhabdomyosarcoma (RMS) is a highly aggressive and rapidly growing sarcoma with skeletal origin that occasionally appears in the spinal epidural space.

Method: We report a 13-year-old girl who presented with back pain, progressive paraparesis, and urinary retention.

Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.

Background: The present study reported a six-year follow up of patients with chronic myeloid leukemia who were on imatinib therapy.

Methods: We performed a retrospective study on a total of 417 patients diagnosed with chronic-phase, Philadelphia-positive (Ph+) chronic myeloid leukemia within six months before study entry. Patients were eligible for the study if they were between 18 and 70 years of age.